News Snapshot:
Biotech JW Bioscience in pancreatic cancer biomarker deal with Immunovia With its patents registered in 25 countries, the biotech firm aims to grow bigger in the global in-vitro diagnostic market By S.Korea's bio-health industry exports log best-ever first half in 2021 JW Bioscience CEO Hahm Eun-kyung (left) signs a licensing deal with Immunovia CEO Patrik Dahlen JW Bioscience Co., a subsidiary of South Korea’s JW Life Science Co., has signed a non-exclusive agreement to transfer its patented technology of detecting early-stage pancreatic cancer to Sweden’s Immunovia AB.Under the deal, the Swedish diagnostic company will have the right to commercialize products...
